Physician profile
Debashis Biswas
NPI 1831144039
$6,232.59
in general payments reported to CMS, 2019-2025
45 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,016 · 2020: $664 · 2021: $312 · 2022: $1,653 · 2023: $122 · 2024: $245 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $586.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $629.14 | 2019-2025 | Tysabri, Vumerity |
| Novartis Pharmaceuticals Corporation | $497.24 | 2019-2022 | |
| Abbvie INC. | $403.19 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Sunovion Pharmaceuticals INC. | $345.63 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $311.91 | 2022 | |
| Sk Life Science, INC. | $309.74 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $292.22 | 2019-2022 | |
| Ucb, INC. | $285.80 | 2019-2024 | Rystiggo |
| Acadia Pharmaceuticals INC | $272.33 | 2019-2022 | |
| Lilly USA, LLC | $255.59 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $242.67 | 2019-2020 | |
| Lundbeck LLC | $209.53 | 2019-2023 | Vyepti |
| Neurocrine Biosciences, INC. | $207.90 | 2022-2025 | Ongentys, Ingrezza |
| Pfizer INC. | $169.63 | 2019-2025 | |
| Emd Serono, INC. | $148.60 | 2019 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debashis Biswas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.